Lavrenov Sergey N, Isakova Elena B, Panov Alexey A, Simonov Alexander Y, Tatarskiy Viktor V, Trenin Alexey S
Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia.
N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia.
Pharmaceuticals (Basel). 2020 Dec 16;13(12):469. doi: 10.3390/ph13120469.
The wide spread of pathogens resistance requires the development of new antimicrobial agents capable of overcoming drug resistance. The main objective of the study is to elucidate the effect of substitutions in (1-indol-3-yl)methylium derivatives on their antibacterial activity and toxicity to human cells. A series of new compounds were synthesized and tested. Their antibacterial activity in vitro was performed on 12 bacterial strains, including drug resistant strains, that were clinical isolates or collection strains. The cytotoxic effect of the compounds was determined using an test with HPF-hTERT (human postnatal fibroblasts, immortalized with hTERT) cells. The activity of the obtained compounds depended on the carbon chain length. Derivatives with C5-C6 chains were more active. The minimum inhibitory concentration (MIC) of the most active compound on Gram-positive bacteria, including MRSA, was 0.5 μg/mL. Compounds with C5-C6 chains also revealed high activity against (1.0 and 0.5 μg/mL, respectively) and moderate activity against Gram-negative bacteria (8 μg/mL) and (2 and 8 μg/mL, respectively). However, they have no activity against and . The most active compounds revealed higher antibacterial activity on MRSA than the reference drug levofloxacin, and their ratio between antibacterial and cytotoxic activity exceeded 10 times. The data obtained provide a basis for further study of this promising group of substances.
病原体耐药性的广泛传播需要开发能够克服耐药性的新型抗菌剂。本研究的主要目的是阐明(1-吲哚-3-基)甲基衍生物中的取代基对其抗菌活性和对人类细胞毒性的影响。合成并测试了一系列新化合物。它们的体外抗菌活性是在12种细菌菌株上进行的,包括临床分离株或保藏菌株中的耐药菌株。使用HPF-hTERT(用人端粒酶逆转录酶永生化的人类产后成纤维细胞)细胞试验测定化合物的细胞毒性作用。所获得化合物的活性取决于碳链长度。具有C5-C6链的衍生物活性更高。最具活性的化合物对包括耐甲氧西林金黄色葡萄球菌(MRSA)在内的革兰氏阳性菌的最低抑菌浓度(MIC)为0.5μg/mL。具有C5-C6链的化合物对[具体细菌1](分别为1.0和0.5μg/mL)也显示出高活性,对革兰氏阴性菌[具体细菌2](8μg/mL)和[具体细菌3](分别为2和8μg/mL)显示出中等活性。然而,它们对[具体细菌4]和[具体细菌5]没有活性。最具活性的化合物对MRSA的抗菌活性高于参考药物左氧氟沙星,并且它们的抗菌活性与细胞毒性活性之比超过10倍。所获得的数据为进一步研究这一有前景的物质组提供了依据。